Skip to main content

About the test

MyCheck Cancer Female assesses tumor-associated mutations that are being passed along from generation to generation.

Cancer is the world’s second deadliest disease, so it’s unfortunate but no surprise that many fami-lies have at least a few members who have had cancer. Sometimes, certain types of cancer seem to run in some families, breast cancer being a very common one. Although this is often referred to as inherited cancer, what is inherited is the abnormal gene that can lead to cancer, not the cancer itself.

Women that inherit these abnormal genes are more susceptible to cancer development. Identify-ing those at high risk enables implementation of additional screening, surveillance, and interven-tions.


People can inherit germline (egg and sperm) mutations in their parents and, with them, the pre-disposition to develop the tumor associated with that alteration.

The MyCheck Cancer Female test must be considered by women if there is:

  • a family history of breast and/or ovarian cancer
  • women with cases of breast cancer diagnosed before age 35 (ovarian cancer before age 40) or who have had multiple cases of breast and/or ovarian cancer
  • a presence of a mutation known in the family environment
  • a diagnosis of male breast cancer, at any age, in the family environment
  • a need to have a personalized assessment of the predisposition to hereditary forms of cancer

What the test evaluates

MyCheck Cancer Female is a susceptibility test, that is, it evaluates the predisposition to de-velop a female hereditary tumor.

Its panel analyzes 74 genes associated with hereditary breast, ovarian, uterine, prostate, colorec-tal, gastric, melanoma, and pancreatic cancers. Individuals with a pathogenic variant in one of these genes have an increased risk of developing certain cancers, many of which may be difficult both to detect and to treat.


MyCheck Cancer Female leverages Next Generation sequencing (NGS) technology to examine regions of the human genome that tend to get missed by other methods of single or hotspot biomarker testing.

The advantages of this test are:

  • It results in risk-reduction and early diagnosis, increasing the chances of successful treatment and survival.
  • It determines the genetic causes of hereditary breast and ovarian cancers in one’s own family.
  • The early identification of mutations allows the launch of an oncological prevention pro-gram based on the monitoring of genetic stability and on lifestyle interventions.

How the test is performed

MyCheck Cancer Female is performed using NGS on the DNA extracted from a peripheral blood sample:

  1. The blood sample is sent to Bioscience laboratories for genetic testing.
  2. DNA is isolated.
  3. The DNA library is then prepared and sequenced on a NGS sequencer.
  4. Seamless integration of our informatics solutions with our sequencing platforms enables quick and intuitive analysis and reporting once the sequencing is completed

Request the test

To request MyCheck Cancer Female, or for more information about the test, please feel free to call us at +971 (0)4 375 722 or fill in this form:

(*) required fields

    How did you hear about us? InternetDoctor/OncologistMagazines/NewspapersRelatives/FriendsOther

    Privacy Policy (*)